Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2020-11-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated November 30, 2020, announcing a change in the total number of outstanding shares and votes due to the exercise of stock options under an incentive program. This directly relates to a change in the company's capital structure (increase in shares and share capital). This aligns best with the 'Share Issue/Capital Change' definition (Code: SHA). It is not a general regulatory filing (RNS) because it describes a specific corporate action related to capital, nor is it a financing update (CAP) which usually implies raising external capital through debt or equity issuance to investors, but rather an internal capital structure adjustment via options.
2020-11-30 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated November 30, 2020, announcing a change in the number of outstanding shares and votes due to the exercise of warrants under an incentive program. This action directly results in an increase in share capital. This type of announcement, detailing changes to the company's share structure (new shares issued via warrant exercise), fits best under the 'Share Issue/Capital Change' category (SHA). It is not a general regulatory filing (RNS) because it is highly specific to capital structure, nor is it a Director's Dealing (DIRS) or a financing announcement (CAP), which usually relates to raising external capital through debt or equity offerings rather than internal warrant exercises.
2020-11-30 English
Report Publication Announcement 2020
Report Publication Announcement Classification · 1% confidence The document is titled "DELÅRSRAPPORT Q3 2020" (Interim Report Q3 2020) and contains detailed financial summaries for the period July - September 2020, including Net Sales, Net Income, and Earnings Per Share, along with key business and regulatory updates for the quarter. The structure, content (financial tables, management discussion), and explicit naming convention ('Delårsrapport Q3') strongly indicate a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a comprehensive report, not just the initial highlights, and it is not a 10-K as it covers only Q3.
2020-11-19 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q3 2020' and contains comprehensive financial statements, including a 'Financial overview of the group' with comparative data for the period, a CEO statement, and detailed operational updates. It is clearly a quarterly financial report, not an announcement of one, and contains substantive financial data. Q3 2020
2020-11-19 English
Extra bolagsstämma i Oncopeptides AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice in Swedish titled "Extra bolagsstämma i Oncopeptides AB (publ)" which translates to "Extra General Meeting in Oncopeptides AB (publ)". It details the procedures for holding an Extraordinary General Meeting (EGM) via advance voting due to COVID-19, outlines the right to participate, and presents a detailed agenda. The agenda items (points 7a, 7b, 7c, 7d) specifically concern proposals for establishing a performance-based long-term incentive program for US employees, including the issuance of warrants and stock swap agreements. This content—a formal notice calling for a shareholder meeting and detailing the proposals to be voted upon—is characteristic of materials sent to shareholders to solicit their votes and provide necessary information prior to the meeting. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI). It is not the minutes of the meeting (AGM-R), nor is it a general earnings release (ER) or a full annual report (10-K).
2020-11-03 Swedish
Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled 'Extraordinary General Meeting in Oncopeptides AB (publ)' and provides notice for shareholders to attend this meeting via advance voting (postal voting). The agenda items listed (e.g., election of chairman, approval of minutes, resolution on the introduction of a long term incentive program) are standard items for a shareholder meeting. This content directly relates to the formal proceedings and materials associated with a General Meeting, specifically an Extraordinary General Meeting (EGM). Therefore, the most appropriate classification is AGM-R (AGM Information), as EGM materials often fall under this umbrella for general shareholder meeting documentation, especially when dealing with resolutions and voting procedures.
2020-11-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.